skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Human pharmacokinetics of iohexol. A new nonionic contrast medium

Abstract

The pharmacokinetics of iohexol, a new nonionic, water-soluble contrast medium, have been determined after intravenous injection in 20 healthy volunteers, at four different dose levels (125-500 mg I/kg). The apparent volume of distribution was 0.27 1/kg, indicating distribution in the extracellular water. The biologic half-life was 121 minutes, comparable with that of other intravascular contrast media. Iohexol was excreted completely unmetabolized in the urine, with a 100% recovery 24 hours after injection. A comparison of iohexol and chromium-51 (/sup 51/Cr)-EDTA clearances indicates that iohexol is mainly excreted by glomerular filtration. The /sup 51/Cr-EDTA clearance was the same when injected separately and concomitantly with iohexol, indicating that glomerular filtration rate is not affected by iohexol. No dose dependency was observed in the investigated parameters t1/2 alpha, t1/2 beta, Vd, ClT or ClR. Iohexol pharmacokinetics are in correspondence with previously reported data on intravascular contrast media.

Authors:
; ; ;
Publication Date:
Research Org.:
Nyegaard and Co., Oslo, Norway
OSTI Identifier:
5023335
Resource Type:
Journal Article
Journal Name:
Invest. Radiol.; (United States)
Additional Journal Information:
Journal Volume: 18:2
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; IOHEXOL; EXCRETION; METABOLISM; BIOLOGICAL HALF-LIFE; CHROMIUM 51; CONTRAST MEDIA; EDTA; KIDNEYS; MAN; AMINO ACIDS; ANIMALS; BETA DECAY RADIOISOTOPES; BODY; CARBOXYLIC ACIDS; CHELATING AGENTS; CHROMIUM ISOTOPES; CLEARANCE; ELECTRON CAPTURE RADIOISOTOPES; EVEN-ODD NUCLEI; INTERMEDIATE MASS NUCLEI; ISOTOPES; MAMMALS; NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PRIMATES; RADIOISOTOPES; VERTEBRATES; 550602* - Medicine- External Radiation in Diagnostics- (1980-); 550601 - Medicine- Unsealed Radionuclides in Diagnostics

Citation Formats

Olsson, B., Aulie, A., Sveen, K., and Andrew, E. Human pharmacokinetics of iohexol. A new nonionic contrast medium. United States: N. p., 1983. Web. doi:10.1097/00004424-198303000-00015.
Olsson, B., Aulie, A., Sveen, K., & Andrew, E. Human pharmacokinetics of iohexol. A new nonionic contrast medium. United States. doi:10.1097/00004424-198303000-00015.
Olsson, B., Aulie, A., Sveen, K., and Andrew, E. Tue . "Human pharmacokinetics of iohexol. A new nonionic contrast medium". United States. doi:10.1097/00004424-198303000-00015.
@article{osti_5023335,
title = {Human pharmacokinetics of iohexol. A new nonionic contrast medium},
author = {Olsson, B. and Aulie, A. and Sveen, K. and Andrew, E.},
abstractNote = {The pharmacokinetics of iohexol, a new nonionic, water-soluble contrast medium, have been determined after intravenous injection in 20 healthy volunteers, at four different dose levels (125-500 mg I/kg). The apparent volume of distribution was 0.27 1/kg, indicating distribution in the extracellular water. The biologic half-life was 121 minutes, comparable with that of other intravascular contrast media. Iohexol was excreted completely unmetabolized in the urine, with a 100% recovery 24 hours after injection. A comparison of iohexol and chromium-51 (/sup 51/Cr)-EDTA clearances indicates that iohexol is mainly excreted by glomerular filtration. The /sup 51/Cr-EDTA clearance was the same when injected separately and concomitantly with iohexol, indicating that glomerular filtration rate is not affected by iohexol. No dose dependency was observed in the investigated parameters t1/2 alpha, t1/2 beta, Vd, ClT or ClR. Iohexol pharmacokinetics are in correspondence with previously reported data on intravascular contrast media.},
doi = {10.1097/00004424-198303000-00015},
journal = {Invest. Radiol.; (United States)},
number = ,
volume = 18:2,
place = {United States},
year = {1983},
month = {3}
}